875110-45-5Relevant academic research and scientific papers
Nickel-Catalyzed Cross-Electrophile Coupling Reactions for the Synthesis of gem-Difluorovinyl Arenes
Xiong, Baojian,Wang, Ting,Sun, Haotian,Li, Yue,Kramer, S?ren,Cheng, Gui-Juan,Lian, Zhong
, p. 13616 - 13623 (2020/11/30)
A nickel-catalyzed cross-electrophile coupling reaction between (hetero)aryl bromides and 2,2-difluorovinyl tosylate is presented. This protocol provides facile incorporation of the gem-difluorovinyl moiety in organic molecules. The method features mild reaction conditions, good functional group tolerance, and excellent yields. Furthermore, mechanistic experiments and DFT studies indicate a Ni(0)/Ni(II) catalytic cycle, thus differing from the currently accepted catalytic cycle for nickel-catalyzed C(sp2)-C(sp2) cross-electrophile coupling reactions.
2,2-Difluorovinyl Pinacolborane – A New Versatile Reagent for the Suzuki–Miyaura Reaction
Blahun, Oleksandr P.,Redka, Mykhailo O.,Voitenko, Zoia V.,Kysil, Andrii I.,Dobrydnev, Alexey V.,Grygorenko, Oleksandr O.
, p. 6417 - 6421 (2019/11/05)
A novel fluorinated reagent for the synthesis of gem-difluorostyrenes and their heterocyclic analogues – 2,2-difluorovinyl pinacolborane (CF2=CHBPin) was developed. In particular, borylation of 1,1-difluoroethylene with isopropoxy pinacolborane
NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES
-
Page/Page column 65, (2008/06/13)
A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is -O-, -CH2-, or -NH-; n is an integer selected between 0 and 1; R6 and R7 each independently is hydrogen or C1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q1 to Q5; Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.
